Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Revance logo — Developing neuromodulators for the treatment of aesthetic an...

Revance

Developing neuromodulators for the treatment of aesthetic and therapeutic conditions

Founded 2002 United States Nashville, United States 669 employees IPO Total: $2.49B Biotechnology, Health Care +2

General Information

Company Name Revance
Founded Year 2002
Location United States Nashville, United States
Founders / Decision Makers
Team member Team member Team member
Employees 669
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Social

BounceWatch is an independent company data service, not affiliated with Revance. To contact Revance, visit revance.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Revance

Revance is a biotechnology company that drives innovation in the development of neuromodulators aimed at addressing both aesthetic and therapeutic conditions.

Founded in 2002 and headquartered in the United States, the company has recently undergone a strategic integration with Crown Laboratories, now operating under the unified name REVANCE. This merger signifies a strengthened approach in the fields of health care, health and wellness, and pharmaceutical industries, showcasing a promising trajectory for growth and innovation.

The most recent financial data reflects a significant investment, with a $924.00M acquisition taking place on 01 August 2024, primarily backed by Crown Laboratories. This sizeable investment underlines the confidence investors have in REVANCE's potential to lead advancements within its industry verticals.

Taxonomy: neuromodulators, aesthetic medicines, dermatology, biopharmaceuticals, RT001, topical botulinum toxin, cosmetic treatments, hyperhidrosis treatment, dermatologic indications, pharmaceuticals, therapeutic conditions, medical aesthetics

Services & Products

Innovative Aesthetics Solutions
Skincare Product Development
Neuromodulator Therapies
Clinical Trial Sponsorship
Medical Education Grants

Target Customers

Patients Seeking Aesthetic Treatments Dermatology Professionals Healthcare Providers Consumers with Skincare Needs Medical Researchers

Funding Rounds & Investors (17)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $924.00M 1
Crown Laboratories
01 Aug 2024
Post-IPO Equity $100.00M -
01 Mar 2024
Post-IPO Equity $200.00M -
01 Sep 2022
Post-IPO Debt $300.00M 1
Athyrium Capital Management
Athyrium Capital Management
01 Mar 2022
Post-IPO Debt $250.00M -
01 Feb 2020
Post-IPO Equity $115.00M -
01 Jan 2019
Post-IPO Equity $167.10M -
01 Dec 2017
Post-IPO Equity $126.00M -
01 Nov 2015
Post-IPO Equity $131.30M -
01 Jun 2014
IPO Undisclosed -
01 Feb 2014

View All 17 Funding Rounds

Revance Alternatives & Competitors

Revance vs
PHISKIN
PHISKIN China

Specializing in advanced skin and laser treatments, located in China.

Private Equity
22 employees
Health Care, Health and Wellness
Revance vs
Dermira, Inc.
Dermira, Inc. United States

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatolog...

Post-IPO Equity
24 employees
Biopharma, Biotechnology
Revance vs
Derm & Rejuvenation Institute
Derm & Rejuvenation Institute United States

Dr. Kormeili is an internationally recognized dermatologist offering medical, surgical, and cosmetic...

4 employees
Health Care, Health and Wellness

FAQ About Revance

Developing neuromodulators for the treatment of aesthetic and therapeutic conditions
Revance was founded in 2002.
Revance is headquartered in Nashville, United States.
Revance operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on neuromodulators, aesthetic medicines, dermatology and biopharmaceuticals. Its customers include Patients Seeking Aesthetic Treatments, Dermatology Professionals and Healthcare Providers.
Revance has approximately 669 employees.
Revance has completed 17 funding rounds, raising a total of $2.49B. The latest funding stage is IPO.
Revance offers: Innovative Aesthetics Solutions, Skincare Product Development, Neuromodulator Therapies, Clinical Trial Sponsorship, Medical Education Grants.
Top alternatives and competitors to Revance include PHISKIN, Dermira, Inc., Derm & Rejuvenation Institute, Energist, Eirion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Revance and PHISKIN are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Revance, https://bouncewatch.com/company/revance, updated 3 October 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes